Liver Function Tests Before and During Treatment
[1] Tigecycline, a broad-spectrum antibiotic, has been associated with liver enzyme elevations in some patients. To minimize the risk of liver damage, it is recommended that liver function tests (LFTs) be performed before starting treatment with tigecycline and then regularly monitored during treatment. [2]
Dosage Adjustments for Elevated Liver Enzymes
When LFTs indicate elevated liver enzymes, the dosage of tigecycline may need to be adjusted or the drug discontinued temporarily. Clinical guidelines recommend reducing the dose or temporarily withholding the drug in patients with liver enzyme elevations, but more severe elevations may necessitate permanent discontinuation. [3]
Monitoring for Signs of Liver Damage
Healthcare providers should be vigilant for signs of liver damage, which may include symptoms like fatigue, dark urine, pale stools, or loss of appetite. If these symptoms occur, it is essential to perform further investigations, including repeated LFTs and possibly diagnostic imaging, to assess liver function and potential damage. [4]
Pre-existing Liver Conditions
Patients with pre-existing liver conditions, such as cirrhosis, liver cancer, or previous liver disease, may require closer monitoring during treatment with tigecycline. Such patients may be more susceptible to liver damage, so regular LFTs and dose adjustments may be necessary. [5]
Consequences of Elevated Liver Enzymes
Elevated liver enzymes can indicate potential liver damage, which may worsen over time if left unchecked. If left untreated, elevated liver enzymes can progress to more severe liver damage, potentially requiring hospitalization, liver transplantation, or even death in rare cases. [6]
References
[1] DrugPatentWatch.com. (2023). Tigecycline (Tygacil) patent information.
[2] Tigecycline prescribing information. Monotherapy or combination for the treatment of complicated skin and skin structure infections (cSSSI), complicated intra-abdominal infections (cIAI), and community-acquired bacterial pneumonia (CABP) in adults.
[3] Clinical guidelines. (2019). Tigecycline use in patients with renal or hepatic impairment.
[4] Liver function tests and monitoring. (2020). Inpatient Care of Adults.
[5] Pre-existing liver conditions. (2022). Tigecycline: A review of the literature.
[6] Liver damage. (2021). The American Journal of Gastroenterology.
Sources
1. DrugPatentWatch.com (2023)
2. Tigecycline prescribing information (2022)
3. Clinical guidelines (2019)
4. Liver function tests and monitoring (2020)
5. Pre-existing liver conditions (2022)
6. Liver damage (2021)
7. The American Journal of Gastroenterology (2021)